ALS progression

PrimeC, a treatment candidate for amyotrophic lateral sclerosis (ALS), was found to significantly slow disease progression in certain subgroups of patients in the ongoing PARADIGM Phase 2b trial, according to new data announced by its developer NeuroSense Therapeutics. Benefitting most were people at high risk of rapid disease…

A blood biomarker of oxidative stress, a type of cellular stress implicated in amyotrophic lateral sclerosis (ALS), is significantly increased in ALS patients and its levels seem to correlate with disease progression and survival. That’s according to a recent analysis of study data from Coya Therapeutics, with the…

Treatment with Qalsody (tofersen) in the real world slowed disease progression in people with amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations, a small study reports. It also stabilized patients’ quality of life and lowered levels of nerve damage-related biomarkers, which is consistent with clinical trial data that…

SLS-005 did not significantly slow amyotrophic lateral sclerosis (ALS) progression compared with a placebo in the HEALEY platform trial, according to top-line data showing that the experimental therapy did not ease functional declines nor extend patient survival. The therapy, developed by Seelos Therapeutics, also failed to slow…

Daily treatment with monepantel — a drug widely used in veterinary medicine — was shown to reduce the rate of disease progression by as much as 58% in people with amyotrophic lateral sclerosis (ALS) or motor neuron disease (MND), according to top-line data from a Phase 1 trial.

New data show that blood-based measures, including levels of markers of nerve damage and chemical DNA modifications, can help predict which individuals with amyotrophic lateral sclerosis (ALS) will have faster disease progression over time. However, because the disease course may be altered with Radicava or Radicava ORS —…

Denali Therapeutics’ SAR443820 (DNL788) treatment candidate — now in late-stage clinical testing for amyotrophic lateral sclerosis (ALS), per the company’s website — has failed to significantly slow disease progression in adults in a Phase 2 trial. The experimental therapy “did not meet the primary endpoint of change” in outcomes…

Up to three years of daily treatment with the investigational therapy IPL344 was well tolerated and slowed disease progression among adults with amyotrophic lateral sclerosis (ALS), according to top-line data from a small Phase 1/2a clinical trial. Preliminary efficacy analyses also indicated that IPL344 might be able to…

Note: This story was updated Jan 24, 2024, to correct that Radicava and Radicava Oral Suspension are available in Switzerland but not in other European countries. FAB122, an oral formulation of edaravone developed by Ferrer, failed to slow disease progression or extend survival in adults with amyotrophic lateral…

A memory from 12 years ago popped up on my Facebook feed. It was a video we had made for a benefit my husband’s co-workers organized for him after his ALS diagnosis. “When I was diagnosed I thought of Danny,” Todd says at the start of the video, accompanied…